WO2005089871A1 - Utilisation d’un compose antagoniste d’au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour la preparation d’une composition pharmaceutique destinee a traiter la rosacee - Google Patents
Utilisation d’un compose antagoniste d’au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour la preparation d’une composition pharmaceutique destinee a traiter la rosacee Download PDFInfo
- Publication number
- WO2005089871A1 WO2005089871A1 PCT/FR2005/000367 FR2005000367W WO2005089871A1 WO 2005089871 A1 WO2005089871 A1 WO 2005089871A1 FR 2005000367 W FR2005000367 W FR 2005000367W WO 2005089871 A1 WO2005089871 A1 WO 2005089871A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor
- use according
- group
- chosen
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Definitions
- the present invention relates to the field of rosacea treatment.
- the invention aims to provide new pharmaceutical compositions, more particularly dermatological compositions, useful for the treatment of rosacea and comprising, as active agent, an antagonist compound of at least one receptor chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
- Rosacea is a common chronic and progressive inflammatory dermatosis linked to5 vascular relaxation. It mainly affects the central part of the face and is characterized by flushing of the face or flushing, facial erythema, papules, pustules, and telangiectasia. In severe cases, especially in men, the soft tissue in the nose can swell and produce a bulbous swelling called rhinophyma. Rosacea usually occurs between the ages of 25 and 70, and is much more common in people fair complexion. It affects more particularly women, although this condition is generally more severe in men. Rosacea is chronic and persists for years with periods of exacerbation and remission.
- Rosacea was originally called "acne rosacea” because its papules (slight raised skin) and inflammatory pustules (scabs of pus) are very similar to those of acne vulgaris. Unlike acne vulgaris, 0 the petiology of which is based on both abnormal keratinization, increased sebum production and bacterial inflammation, inflammation of rosacea is vascular in nature and poorly understood. This facial vascular anomaly results in permanent edema of the dermis which could accompany increased colonization by Demodex folliculorum, a mite which is usually found in the follicles of the face.
- Demodex folliculorum has an etiological role in rosacea (Erbagi et al., 1998, Int J Dermatol, vol.37, pages 421-425; Purcell et al, 1986, J Am Acad Dermatol, vol.15, pages 1159-1162; Sibenge et al., 1992, J Am Acad Dermatol, vol. 26, pages 590-593). It seems that Demodex folliculorum causes or worsens inflammatory reactions, resulting in papules and pustules, by blocking the pilosebaceous follicles of the face (Roihu et al., 1998, J Cutan Pathol, vol.25, pages 550-552 ).
- rosacea The pathogenesis of rosacea is poorly understood. Many factors can be involved without necessarily inducing this condition. These are for example psychological factors, gastrointestinal disorders, environmental factors (exposure to the sun, temperature, humidity) and emotional factors (stress), food (alcohol, spices), hormonal, vascular, or even infection with Helicobacter pilori.
- Rosacea develops in 4 stages, but passing through all stages is not compulsory: - stage 1 of vascular relaxations (around 20 years). Patients have sudden onset of paroxysmal redness of the face and neck, with a feeling of warmth, but without systemic signs. After the attacks, the skin of the face becomes normal again. These "flushes” are triggered by changes in temperature (sometimes leading to thermophobia), the absorption of hot drinks or alcohol. - stage 2 erythematato-telangiectatic (around 30 years). The malar areas are diffusely red. We observe dilated capillaries constituting the classic rosacea. Unlike stage 1, the redness is permanent. In addition to the cheeks, the chin and the middle part of the forehead can be affected.
- stage 3 of papulo-pustules (around 40 years).
- erythema develop papules and pustules a few millimeters in diameter, without associated comedones.
- This dermatosis can be very widespread, sometimes on the glabrous part of the scalp in men, but respects the periphery of the goat and the eyes.
- Patients complain of sensitive skin, with subjective intolerance to most oily topicals and cosmetics.
- - stage 4 of rhinophyma (around 50 years or later). This late phase mainly affects men, unlike the other stages.
- the nose is enlarged, diffusely red and the follicular orifices are dilated.
- the skin gradually thickens.
- Minor forms of rosacea can be treated with active ingredients such as anti-seborrheics and anti-infectives, for example benzoyl peroxide, retinoic acid, metronidazole.
- active ingredients such as anti-seborrheics and anti-infectives, for example benzoyl peroxide, retinoic acid, metronidazole.
- Metronidazole, or (methyl-2-nitro-5-imidazolyl) -2- ethanol is known in the prior art for its antibacterial, antiparasitic and antiprotozoal properties. It exerts a selective toxicity with respect to anaerobic microorganisms as well as hypoxic cells. At the level of the latter, metronidazole is reduced to derivatives capable of altering the DNA structure of these cells.
- the work of the Applicant has made it possible to demonstrate the usefulness of the receptor antagonist compounds chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin in the treatment of rosacea.
- Beta-adrenergic receptors are involved in the regulation of various physiological functions, such as metabolic activity, cardiac activity, respiration, central nervous system activity, blood pressure and vascular tone.
- the 5-HT2 receptors the 5-HT5 receptors belong to the family of serotonin (5-HT) receptors. All of the 5-HT receptors are coupled to G proteins, except 5-HT3 which is an ion channel. Activation of 5-HT2 receptors stimulates the activity of phospholipase C.
- the transduction system of 5-HT5 receptors is positively associated with adenylate cyclase.
- the AT1 receptor is involved in the regulation of vasoconstriction by angiotensin II.
- angiotensin II increases the tone of the subcutaneous arteries.
- Galanine is a peptide of 29 amino acids found in the central nervous system. According to certain studies, galanine has a role in the modulation of the cutaneous vascular reaction and in inflammation (Pincelli, 1990, Br J Dermatol, vol. 122, pages 745-750).
- the work of the Applicant has made it possible to demonstrate the involvement of beta-adrenergic receptor antagonists, of the AT1 receptor, of the 5-HT2 receptor, of the 5-HT5 receptor, and of the galanin receptor in the treatment of rosacea .
- This activity has been demonstrated by the use of metronidazole which results in an interaction with beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor. More specifically, it has been found that the use of metronidazole inhibits the binding of natural ligands to these receptors.
- the invention aims to offer a new method of treating rosacea consisting in administering to a subject suffering from rosacea an effective amount of an antagonist compound of at least one receptor chosen from the group comprising beta-adrenergic receptors , the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
- the invention relates more particularly to the use of an antagonist compound of at least one receptor chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor , and the galanin receptor, for the preparation of a pharmaceutical composition for the treatment of rosacea.
- the invention also relates to the use of a compound antagonist of two receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanine, for the preparation of a pharmaceutical composition defined as above.
- the invention also relates to the use of a compound antagonist of three receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanine for the preparation of a pharmaceutical composition defined as above.
- the invention also relates to the use of an antagonist compound of four receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanine for the preparation of a pharmaceutical composition defined as above.
- the invention also relates to the use of an antagonist compound of five receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanine for the preparation of a pharmaceutical composition defined as previously.
- antagonist compound is meant according to the present invention, any molecule which inhibits the binding of at least one agonist or a natural ligand to its receptor.
- beta-adrenergic receptor antagonist compounds By way of nonlimiting examples of beta-adrenergic receptor antagonist compounds, mention may be made of metropobol, esmolol, acebutolol, timolol, pindolol and labetolol.
- composition which is the subject of the present invention is a dermatological composition, for topical administration on the skin.
- rosacea treatment is understood to mean, according to the present invention, the treatment and / or prevention of rosacea, in one or more of the stages described above.
- the composition is intended for the treatment of the first stage of rosacea.
- the composition is intended for the treatment of the second stage of rosacea.
- the composition is intended for the treatment of the third stage of rosacea.
- the composition is intended for the treatment of the fourth stage of rosacea.
- the composition contains 0.0001 to 20% by weight, preferably from 0.1 to 2%, and more preferentially of the order of 0.75 to 1% of an antagonist such as defined above.
- the present invention relates, in addition to the use of an antagonist as defined above, the use of derivatives thereof.
- derivatives means compounds which are distinguished from the antagonist as defined above by substitution, addition or deletion of one or more chemical groups.
- compositions of the invention comprise, in addition to the antagonist as defined above, at least one other therapeutic agent capable of increasing the effectiveness of the treatment.
- at least one other therapeutic agent capable of increasing the effectiveness of the treatment.
- antibiotics antibacterials, antivirals, antiparasitics, antifungals, anesthetics, analgesics, antiallergics, retinoids, anti-free radicals, antipruritics, keratolytics, antiseborrheics, antihistamines, sulfides, immunosuppressive or antiproliferative products.
- the antagonist compound is not metronidazole.
- the composition of the present invention also contains metronidazole.
- the invention also relates to a method of identifying an antagonist compound of at least one receptor chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor: a) bringing the specific radiolabelled ligand into contact with the recombinant human protein of each receptor in a sample; b) bringing the radiolabelled specific ligand and the excess non-radiolabelled specific ligand into contact with the recombinant human protein of each receptor in another sample; c) Addition of the compound to be tested in the two samples; d) Measurement of radioactivity by counting the scintillation in the two samples; e) Calculation of the difference in radioactivity measured in the two samples; f) Selection of said compounds for which a reduction in radioactivity is obtained in step e) relative to the control value obtained with the receptors not brought into contact with the compound to be tested.
- compositions of the invention may also comprise any additive usually used in the pharmaceutical, dermatological field, compatible with the antagonist as defined above. Mention may in particular be made of sequestrants, antioxidants, sun filters, preservatives, for example DL-alpha-tocopherol, fillers, electrolytes, humectants, dyes, bases or common acids, inorganic or organic, perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds such as DHA, soothing and protective agents for the skin such as pallantoin, skin penetrating agents, gelling.
- sequestrants for example DL-alpha-tocopherol
- fillers electrolytes, humectants, dyes, bases or common acids, inorganic or organic, perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds such as DHA, soothing and protective agents for the skin such as pallanto
- additives can be present in the composition in an amount of 0 to 20% by weight relative to the total weight of the composition.
- sequestering agents examples include ethylenediaminetetraacetic acid (EDTA), as well as its derivatives or its salts, dihydroxyethylglycine, citric acid, tartaric acid, or mixtures thereof.
- EDTA ethylenediaminetetraacetic acid
- preservatives examples include benzalkonium chloride, phenoxyethanol, benzyl alcohol, diazolidinylurea, parabens, or mixtures thereof.
- humectants examples include glycerin and sorbitol.
- compositions of the invention may contain one or more penetrating agents in preferential concentrations ranging from 0 to 20% and more preferably ranging from 0.6 to 3% by weight relative to the total weight of the composition.
- penetrating agents use is preferably made, without this list being limiting, of compounds such as propylene glycol, dipropylene glycol, propylene glycol dipelargonate, lauroglycol, ethoxydiglycol.
- compositions according to the invention may also contain one or more surfactants in preferential concentrations ranging from 0 to 10% and more preferably ranging from 0.1 to 2%.
- compositions of the present invention may be in all the galenical forms normally used for topical application, in particular in the form of aqueous, hydroalcoholic or oily solutions, of lotion-type dispersions, of aqueous, anhydrous or lipophilic gels, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or of suspensions or emulsions of consistency soft, semi-liquid or solid of the cream, gel or ointment type or else micro-emulsions, micro-capsules, micro-particles or vesicular dispersions of ionic and / or non-ionic type.
- the creams can be formulated from a mixture of mineral oil, or a mixture of beeswax and water which instantly emulsifies, in which the antagonist compound as defined above is added, dissolved in a small amount of oil such as almond oil.
- the ointments can be formulated by mixing a solution of said antagonist in an oil such as almond oil in heated paraffin, then allowing the mixture to cool.
- compositions according to the invention mention may be made of those comprising an active phase containing (expressed as a percentage by weight):
- - 0 to 90% preferably 5 to 25%, especially 10 to 20%, of water; - 0 to 10%, preferably 0 to 2%, especially 0 to 0.5%, of surfactant;
- aqueous phase comprising a gelling agent, and water.
- the aqueous phase of a composition according to the invention in the form of an emulsion may comprise water, floral water such as blueberry water, or natural thermal or mineral water, for example chosen from Vittel water, Vichy basin water, Uriage water, Roche Posay water, Bourboule water, Enghien-les-Bains water, Saint Gervais-les-Bains, water from Néris- les-Bains, water from Allevard-les-Bains, water from Digne, water from Maizines, water from Neyrac-les-Bains, water from Lons-le-Saunier, Eaux Bonnes, water from Rochefort, water from Saint Christau, water from Fumades and water from Tercis-les-bains, water from Avène or Aix les Bains water.
- Said aqueous phase may be present at a content of between 10 and 90% by weight relative to the total weight of the composition, preferably between 20 and 80% by weight.
- gelling agents of the polyacrylamide family such as the Sodium acryloyldimethyltaurate copolymer / isohexadecane / polysorbate 80 mixture sold under the name Simulgel 600 by the company Seppic, the polyacrylamide / isoparaffin C13-14 / laureth-7 mixture such as, for example, that sold under the name Sepigel 305 by the company Seppic, the family of acrylic polymers coupled to hydrophobic chains such as PEG-150 / decyl / SMDI copolymer sold under the name of Aculyn 44 (polycondensate comprising at least as elements, a polyethylene glycol containing 150 or 180 moles of ethylene oxide, decyl alcohol and methylene bis (4-cyclohexylisocyanate) (SMDI), 35% by weight in a mixture of propylene glycol (39%) and water (26%)), the family of modified starches such as modified potato starch sold under the
- the gelling agent as described above can be used at preferential concentrations ranging from 0.1 to 15% and, more preferably, ranging from 0.5 to 5%.
- the gels can preferably be prepared by dispersing or dissolving the metronidaole in an appropriate ratio, in a gel of the carbomer, poloxamer or cellulosic type.
- metronidazole as a receptor antagonist chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5 receptor -HT5, and the galanin receptor.
- Example 1 Measurement of the binding to beta-1 and beta-2 adrenergic receptors, AT1. 5-HT fi ⁇ . 5-HT ? A and galanine
- beta-1 and beta-2 adrenergic receptor binding test was carried out according to the method described by Smith and Generaler 1999, Cardiovasc Drug Ther, vol. 13, pages 123-126.
- the AT1 receptor binding test was carried out according to the method described by Bergsma et al, 1992, Biochem Biophys Res Comm, vol. 183, pages 989-995.
- the 5-HT 5A receptor binding test was carried out according to the method described by Ress et al, 1994, FEBS Lett, vol. 355, pages 242-246.
- the 5-HT 2A receptor binding test was carried out according to the method described by Bonhauss et al, 1995, Brit J Pharmacol, vol. 1155, pages 622-628.
- the galanin receptor binding test was carried out according to the method described by Sullivanet al, 1997, Biochem Biophys Res Comm, vol. 233, pages 823-828.
- the binding of metronidazole to each receptor was determined by competitive experiments.
- the receptor a recombinant human protein, was incubated according to the times indicated in Table 1 below, with a single concentration of labeled specific ligand, in the presence of metronidazole at 10 ⁇ M. Bound radioactivity was measured by scintillation counting. Table 1
- the specific binding of the ligand to the receptor is defined as the difference between the total binding and the non-specific binding determined in the presence of an excess of unlabeled ligand.
- Metronidazole therefore inhibits binding to beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002553208A CA2553208A1 (fr) | 2004-02-20 | 2005-02-17 | Utilisation d'un compose antagoniste d'au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour lapreparation d'une composition pharmaceutique destinee a traiter la rosacee |
US10/590,077 US20070275978A1 (en) | 2004-02-20 | 2005-02-17 | Of at Use of an Antagonist Compound of at Least One Receptor Selected From a Group Comprising Beta-Adrenergic Receptors, A at1, 5-Ht5 and Galanin Receptor for Preparing a Pharmaceutical Composition for Treating Rosacea |
EP05729329A EP1722855A1 (fr) | 2004-02-20 | 2005-02-17 | Utilisation d'un compose antagoniste d'au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour la preparation d'une composition pharmaceutique destinee a traiter la rosacee |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR04/01715 | 2004-02-20 | ||
FR0401715A FR2866567A1 (fr) | 2004-02-20 | 2004-02-20 | Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005089871A1 true WO2005089871A1 (fr) | 2005-09-29 |
Family
ID=34833940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/000367 WO2005089871A1 (fr) | 2004-02-20 | 2005-02-17 | Utilisation d’un compose antagoniste d’au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour la preparation d’une composition pharmaceutique destinee a traiter la rosacee |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070275978A1 (fr) |
EP (1) | EP1722855A1 (fr) |
CA (1) | CA2553208A1 (fr) |
FR (1) | FR2866567A1 (fr) |
WO (1) | WO2005089871A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201990041A1 (ru) * | 2016-06-16 | 2019-05-31 | Альмиралль, С.А. | Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении |
AU2017285258A1 (en) * | 2016-06-16 | 2019-01-24 | Almirall, S.A. | Compositions comprising timolol and an anti-inflammatory agent |
JP2023533911A (ja) * | 2020-07-10 | 2023-08-07 | チャン グァン メモリアル ホスピタル,リンコウ | 上皮成長因子受容体阻害剤によって誘発される上皮細胞損傷を軽減し及び癌細胞を阻害する組成物の製造のための、β-1アドレナリン受容体アンタゴニストの使用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991002527A1 (fr) * | 1989-08-21 | 1991-03-07 | Beth Israel Hospital Association | Procede et composition de traitement d'hypersensibilite cutanee, oculaire et des muqueuses, d'etats inflammatoires et hyperproliferatifs en utilisant des preparations topiques d'antagonistes de serotonine |
WO1998031335A2 (fr) * | 1997-01-16 | 1998-07-23 | L'oreal | Utilisation d'un antagoniste et/ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue |
WO2000029009A1 (fr) * | 1998-11-18 | 2000-05-25 | Coastside Bio Resources | Peptides presentant une activite anticancereuse et anti-inflammatoire |
WO2001035965A1 (fr) * | 1999-11-18 | 2001-05-25 | Bolla John D | Traitement de l'acne rosacee |
-
2004
- 2004-02-20 FR FR0401715A patent/FR2866567A1/fr active Pending
-
2005
- 2005-02-17 CA CA002553208A patent/CA2553208A1/fr not_active Abandoned
- 2005-02-17 US US10/590,077 patent/US20070275978A1/en not_active Abandoned
- 2005-02-17 WO PCT/FR2005/000367 patent/WO2005089871A1/fr not_active Application Discontinuation
- 2005-02-17 EP EP05729329A patent/EP1722855A1/fr not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991002527A1 (fr) * | 1989-08-21 | 1991-03-07 | Beth Israel Hospital Association | Procede et composition de traitement d'hypersensibilite cutanee, oculaire et des muqueuses, d'etats inflammatoires et hyperproliferatifs en utilisant des preparations topiques d'antagonistes de serotonine |
WO1998031335A2 (fr) * | 1997-01-16 | 1998-07-23 | L'oreal | Utilisation d'un antagoniste et/ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue |
WO2000029009A1 (fr) * | 1998-11-18 | 2000-05-25 | Coastside Bio Resources | Peptides presentant une activite anticancereuse et anti-inflammatoire |
WO2001035965A1 (fr) * | 1999-11-18 | 2001-05-25 | Bolla John D | Traitement de l'acne rosacee |
Non-Patent Citations (7)
Title |
---|
BERGSMA D J ET AL: "CLONING AND CHARACTERIZATION OF A HUMAN ANGIOTENSIN II TYPE 1 RECEPTOR", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 183, no. 3, 1992, pages 989 - 995, XP002145165, ISSN: 0006-291X * |
ELLIS C N ET AL: "THE TREATMENT OF PERIORAL DERMATITIS, ACNE ROSACEA, AND SEBORRHEIC DERMATITIS", MEDICAL CLINICS OF NORTH AMERICA, W. B. SAUNDERS COMPANY, PHILADELPHIA, US, vol. 66, no. 4, July 1982 (1982-07-01), pages 819 - 830, XP008034382, ISSN: 0025-7125 * |
JI R-R ET AL: "CENTRAL AND PERIPHERAL EXPRESSION OF GALANIN IN RESPONSE TO INFLAMMATION", NEUROSCIENCE, NEW YORK, NY, US, vol. 68, no. 2, September 1995 (1995-09-01), pages 563 - 576, XP001203559, ISSN: 0306-4522 * |
REBORA A: "The red face: rosacea.", CLINICS IN DERMATOLOGY. 1993 APR-JUN, vol. 11, no. 2, April 1993 (1993-04-01), pages 225 - 234, XP009039132, ISSN: 0738-081X * |
REES S ET AL: "CLONING AND CHARACTERISATION OF THE HUMAN 5-HT5A SEROTONIN RECEPTOR", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 355, 1994, pages 242 - 246, XP002919143, ISSN: 0014-5793 * |
SULLIVAN K A ET AL: "PHARMACOLOGICAL CHARACTERIZATION AND TISSUE DISTRIBUTION OF THE HUMAN AND RAT GALR1 RECEPTORS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 233, 1997, pages 823 - 828, XP001184100, ISSN: 0006-291X * |
WILKIN J K: "Recognizing and managing rosacea", DRUG THERAPY 1993 UNITED STATES, vol. 23, no. 6, 1993, pages 41 - 49, XP009039131, ISSN: 0001-7094 * |
Also Published As
Publication number | Publication date |
---|---|
FR2866567A1 (fr) | 2005-08-26 |
CA2553208A1 (fr) | 2005-09-29 |
EP1722855A1 (fr) | 2006-11-22 |
US20070275978A1 (en) | 2007-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005089871A1 (fr) | Utilisation d’un compose antagoniste d’au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour la preparation d’une composition pharmaceutique destinee a traiter la rosacee | |
WO2006032759A1 (fr) | Utilisation du metronidazole en combinaison avec de l'acide azelaique pour le traitement de la rosacee | |
WO2005079770A2 (fr) | Utilisation d'un compose modulateur d'au moins un recepteur choisi parmi le recepteur de type b de l'il 8 et de type 1 de pacap pour la preparation d'une composition pharmaceutique pour traiter la rosacee | |
EP1718296A2 (fr) | Utilisation du metronidazole pour le traitement des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap | |
WO2005089749A2 (fr) | Utilisation du metronidazole pour le traitement d’ un desordre de la vascularisaton cutanee | |
EP1686975A1 (fr) | UTILISATION DU FEPRADINOL POUR LA PREPARATION D’UNE COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE LA ROSACEE | |
EP1686978B1 (fr) | Utilisation de l'idrocilamide pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee | |
WO2005079786A1 (fr) | Utilisation d’un compose modifiant la secretion de l’interleukine 5, de l’interleukine 6 et/ou de l’interleukine 10 pour la preparation d’une composition pharmaceutique destinee a traiter la rosacee | |
WO2005089751A2 (fr) | Utilisation du metronidazole pour le traitement d’une inflammation cutanee | |
FR2862539A1 (fr) | Utilisation du piketoprofen pour la fabrication d'une composition pharmaceutique pour le traitement de la rosacee | |
FR2899475A1 (fr) | Composition pharmaceutique pour le traitement de la rosacee | |
MXPA06009315A (es) | Uso de metronidazol para el tratamiento de un trastorno de la vascularizacion cutanea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005729329 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2553208 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005729329 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10590077 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2005729329 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10590077 Country of ref document: US |